A Clinical Study to Assess the Ability of the Adjuvanted Recombinant-Protein COVID-19 Vaccine Candidate to Generate a Strong Booster Response Regardless of Initial Vaccine Platform Received
Latest Information Update: 06 Sep 2023
At a glance
- Drugs SP 0253 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 31 May 2021 New trial record
- 27 May 2021 According to a Sanofi media release, following encouraging interim results from the recent Phase 2 study, the companies will also begin clinical studies in the coming weeks (booster study program) complement Phase 3 trial.